
    
      During follow-up, it was determined that there was one additional patient on placebo that was
      still receiving treatment as of 06 APR 2010 and therefore 10 patients' data are reported in
      the current CSR addendum, 6 in the sorafenib + GC group and 4 in the placebo + GC group, and
      as before all in the ITT (non-squamous) population.
    
  